Compare GCBC & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCBC | ASMB |
|---|---|---|
| Founded | 1889 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.8M | 440.0M |
| IPO Year | 1998 | 2010 |
| Metric | GCBC | ASMB |
|---|---|---|
| Price | $22.18 | $28.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $43.40 |
| AVG Volume (30 Days) | 7.0K | ★ 94.1K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.82% | N/A |
| EPS Growth | 26.21 | ★ 50.00 |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $4,117,000.00 | N/A |
| Revenue This Year | N/A | $33.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.49 | ★ N/A |
| Revenue Growth | ★ 11.06 | N/A |
| 52 Week Low | $20.00 | $7.76 |
| 52 Week High | $26.04 | $39.71 |
| Indicator | GCBC | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 39.78 | 46.78 |
| Support Level | $21.39 | $26.50 |
| Resistance Level | $23.34 | $30.66 |
| Average True Range (ATR) | 0.58 | 1.42 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 22.29 | 27.35 |
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.